LiverMultiScan, a device that can detect early liver disease using MRI, received FDA approval.
LiverMultiScan, a device that can detect early liver disease using MRI, received 510(k) clearance from the U.S. Food and Drug Administration, Perspectrum Diagnostics announced.
Since its introduction as a research device in 2014, LiverMultiScan is currently being used to assess primary endpoints in clinical trials for investigational therapies to treat non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, the company said in a release.
Perspectrum Diagnostics claims that LiverMultiScan is the only imaging test cleared to detect early-stage liver disease, offering a quantitative liver assessment in a non-invasive 15-minute MRI scan. The device analyzes the native properties of liver tissue and measures liver fat without the need for additional technology or contrast agents. The result is a highly detailed map of the whole liver, which makes it possible to precisely identify regions of disease, Perspectrum said.
“LiverMultiScan is a novel non-invasive imaging technology with the potential to dramatically change the way we approach diagnosis of liver disease,” Colonel Stephen A. Harrison, MD, FACP, FAASLD, Medical Corps USA, said in the release. “Recent published data suggest that this modality can rapidly differentiate normal liver from fibrotic non-alcoholic steatohepatitis and then accurately predict outcomes based on the liver, inflammation, fibrosis score.”[[{"type":"media","view_mode":"media_crop","fid":"43315","attributes":{"alt":"","class":"media-image media-image-right","id":"media_crop_8770959724425","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4718","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 166px; width: 249px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"Scan developed by LiverMultiscan that shows patient has steatohepatitis and high iron.","typeof":"foaf:Image"}}]]
The device is set for a formal launch at the 2014 American Association for the Study of Liver Disease Meeting, November 13-17, 2015 in San Francisco.
[[{"type":"media","view_mode":"media_crop","fid":"43316","attributes":{"alt":"","class":"media-image media-image-right","id":"media_crop_7718000684256","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4719","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 155px; width: 200px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"LiverMultiscan showing images of patient liver.","typeof":"foaf:Image"}}]]
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.